AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference
03 Marzo 2023 - 6:00AM
Business Wire
AVROBIO, Inc. (Nasdaq: AVRO), a leading
clinical-stage gene therapy company working to free people from a
lifetime of genetic disease, today announced that members of its
senior management team are scheduled to participate in a panel
titled “Orphan Neuro Corporate Panel” at Cowen’s 43rd Annual Health
Care Conference on Tuesday, March 7, 2023 at 10:30 AM ET at the
Boston Marriott Copley Place in Boston.
The panel will be webcast live on the Investors section of
avrobio.com and will remain archived for approximately 90 days.
About AVROBIO
Our vision is to bring personalized gene therapy to the world.
We target the root cause of genetic disease by introducing a
functional copy of the affected gene into the patient’s own
hematopoietic stem cells (HSCs), with the goal of durably
expressing the therapeutic protein throughout the body, including
the central nervous system. Our first-in-class pipeline includes
clinical programs for Gaucher disease and cystinosis, as well as
preclinical programs for Hunter syndrome and Pompe disease. Our
proprietary plato® gene therapy platform is scalable for planned
global commercialization. We are headquartered in Cambridge, Mass.
For additional information, visit avrobio.com, and follow us on
Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. These
statements may be identified by words and phrases such as “aims,”
“anticipates,” “believes,” “continue,” “could,” “designed to,”
“estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,”
“plans,” “possible,” “potential,” “predicts,” “projects,” “seeks,”
“strives,” “should,” “will,” and variations of these words and
phrases or similar expressions that are intended to identify
forward-looking statements. These forward-looking statements
include, without limitation, statements regarding our business
strategy for and the potential therapeutic benefits of our
preclinical and clinical product candidates, including without
limitation the use of AVR-RD-02 for the treatment of Gaucher
disease in both a clinical and a compassionate use or named patient
setting, the design, commencement, enrollment and timing of planned
clinical trials, our plans and expectations with respect to the
development of our clinical and preclinical product candidates,
including timing, design, and initiation of our potential clinical
and registration trials and anticipated interactions and
expectations with regulatory agencies, the timing of patient
recruitment and enrollment activities, preclinical, compassionate
use or clinical trial results, product approvals and regulatory
pathways, anticipated benefits of our gene therapy platform
including potential impact on our commercialization activities,
timing and likelihood of success, the expected benefits and results
of our implementation of our plato® platform in our clinical trials
and gene therapy programs, and the expected safety profile of our
preclinical and investigational gene therapies. Any such statements
in this press release that are not statements of historical fact
may be deemed to be forward-looking statements. Results in
preclinical or early-stage clinical trials may not be indicative of
results from later stage or larger scale clinical trials and do not
ensure regulatory approval. You should not place undue reliance on
these statements, or the scientific data presented.
Any forward-looking statements in this press release are based
on AVROBIO’s current expectations, estimates and projections about
our industry as well as management’s current beliefs and
expectations of future events only as of today and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk that any
one or more of AVROBIO’s product candidates will not be
successfully developed or commercialized, the risk of cessation or
delay of any ongoing or planned clinical trials of AVROBIO or our
collaborators, the risk that AVROBIO may not successfully recruit
or enroll a sufficient number of patients for our clinical trials,
the risk that AVROBIO may not realize the intended benefits of our
gene therapy platform, including the features of our plato®
platform, the risk that our product candidates or procedures in
connection with the administration thereof will not have the safety
or efficacy profile that we anticipate, the risk that prior
results, such as signals of safety, activity or durability of
effect, observed from preclinical or clinical trials, will not be
replicated or will not continue in ongoing or future studies or
trials involving AVROBIO’s product candidates, the risk that we
will be unable to obtain and maintain regulatory approval for our
product candidates, the risk that the size and growth potential of
the market for our product candidates will not materialize as
expected, risks associated with our dependence on third-party
suppliers and manufacturers, risks regarding the accuracy of our
estimates of expenses and future revenue, risks relating to our
capital requirements and needs for additional financing, risks
relating to clinical trial and business interruptions resulting
from the COVID-19 outbreak or similar public health crises,
including that such interruptions may materially delay our
enrollment and development timelines and/or increase our
development costs or that data collection efforts may be impaired
or otherwise impacted by such crises, and risks relating to our
ability to obtain and maintain intellectual property protection for
our product candidates. For a discussion of these and other risks
and uncertainties, and other important factors, any of which could
cause AVROBIO’s actual results to differ materially and adversely
from those contained in the forward-looking statements, see the
section entitled “Risk Factors” in AVROBIO’s most recent Quarterly
Report, as well as discussions of potential risks, uncertainties
and other important factors in AVROBIO’s subsequent filings with
the Securities and Exchange Commission. AVROBIO explicitly
disclaims any obligation to update any forward-looking statements
except to the extent required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230303005024/en/
Investor: Christopher F. Brinzey Westwicke, an ICR
Company 339-970-2843 chris.brinzey@westwicke.com
Media: Kit Rodophele Ten Bridge Communications
617-999-9620 krodophele@tenbridgecommunications.com
AVROBIO (NASDAQ:AVRO)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
AVROBIO (NASDAQ:AVRO)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024